Latest developments on Streptococcus suis: An emerging zoonotic pathogen: Part 2

First International Workshop on Streptococcus suis, Beijing, China, 12-13 August 2013 This second and final chapter of the report on the First International Workshop on Streptococcus suis follows on from Part 1, published in the April 2014, volume 9, issue 4 of Future Microbiology. S. suis is a swin...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariela Segura, Han Zheng, Astrid D. De Greeff, George F. Gao, Daniel Grenier, Yongqiang Jiang, Chengping Lu, Duncan Maskell, Kazunori Oishi, Masatoshi Okura, Ro Osawa, Constance Schultsz, Christian Schwerk, Tsutomu Sekizaki, Hilde Smith, Potjanee Srimanote, Daisuke Takamatsu, Jiaqi Tang, Tobias Tenenbaum, Prasit Tharavichitkul, Ngo Thi Hoa, Peter Valentin-Weigand, Jerry M. Wells, Heiman Wertheim, Baoli Zhu, Jianguo Xu, Marcelo Gottschalk
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84903277334&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53627
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Description
Summary:First International Workshop on Streptococcus suis, Beijing, China, 12-13 August 2013 This second and final chapter of the report on the First International Workshop on Streptococcus suis follows on from Part 1, published in the April 2014, volume 9, issue 4 of Future Microbiology. S. suis is a swine pathogen and a zoonotic agent afflicting people in close contact with infected pigs or pork meat. Although sporadic cases of human infections had been reported worldwide, deadly S. suis outbreaks emerged in Asia. The severity of the disease underscores the lack of knowledge on the virulence and zoonotic evolution of this human-infecting agent. The pathogenesis of the infection, interactions with host cells and new avenues for treatments were among the topics discussed during the First International Workshop on S. suis (China 2013). © 2014 Future Medicine Ltd.